Please assess the completion status of the following clinical trial:

Trial Title: Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~A. Healthy Participants and Atopic Mild to Mild-Persistent Asthmatic Participants:~* Participants must be non-smokers or non-regular smokers (1 to 2 cigarettes on the weekend as part of social gathering) for at least 3 months prior to Screening, according to the participant's self-reported medical history. Participants should be willing to (continue to) abstain from smoking from Screening until completion of the last study related activity~* Participants must have a body mass index (BMI: weight in kilogram \[kg\] divided by the height in square meter \[m\^2\]) of 18.0 to 30.0 kg/m\^2, extremes included~* Participants must have a normal 12-lead electrocardiogram (ECG) at Screening including normal sinus rhythm (heart rate between 40 and 100 beats per minute \[bpm\]); QT interval corrected for heart rate according to Fridericia (QTcF) interval less than and equal to (\<=) 450 milliseconds (ms); QRS interval lower than 120 ms; and PR interval \<=220 ms~* Participants must be healthy, with the exception of findings related to asthma and allergy in atopic mild to mild-Persistent asthmatic participants, on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, vital signs (Systolic Blood Pressure \[BP\], Diastolic BP, pulse rate, respiratory rate, and body temperature), and the results of blood biochemistry and hematology tests performed at Screening~* Participants must be willing/ able to adhere to the prohibitions and restrictions specified in the protocol and study procedures~B. Atopic Mild to Mild-Persistent Asthmatic Participants:~* Participants with Investigator-diagnosed mild to mild-persistent asthma based on the Guidelines for the Diagnosis and Management of Asthma~* Participants having a well-established allergen profile (participants have been previously skin tested and, by history, have allergic responses to specific allergens)~* Participants with forced expiratory volume in 1 second (FEV1) greater than (\>) 70 percent (%) of predicted at Baseline~Exclusion Criteria:~A. Healthy Participants and Atopic Mild to Mild-Persistent Asthmatic Participants:~* Participants having a significant (by the assessment of the Investigator) nasal abnormality and/or has a history of nasal or sinus surgery within 12 months of enrollment~* Participants having an upper or lower respiratory tract infection within 4 weeks of enrollment~* Participants with a history or evidence of use of alcohol, barbiturates, amphetamines, recreational or narcotic drug use within the past 1 year, which in the Investigator's opinion would compromise participant's safety and/or compliance with the study procedures~* Participants with a known history of human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection, or with a known history of hepatitis A, B, or C virus infection at study Screening~* Female participants who are breastfeeding at Screening or having a positive urine pregnancy test at Screening~B. Atopic Mild to Mild-Persistent Asthmatic Participants:~* Hospitalization or treatment in an emergency care facility for asthma during the last 3 years~* Participants using nasal corticosteroids on a daily basis in the 4 weeks prior to enrollment~* Participants who have received allergen immunotherapy in the last 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- JNJ-43260295 (Healthy Participants) (Type: EXPERIMENTAL): Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
- Placebo (Healthy Participants) (Type: PLACEBO_COMPARATOR): Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
- JNJ-43260295 (Asthmatic Participants) (Type: EXPERIMENTAL): Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues